BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 7694306)

  • 1. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
    Cesková E; Svestka J
    Pharmacopsychiatry; 1993 Jul; 26(4):121-4. PubMed ID: 7694306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone: clinical safety and efficacy in schizophrenia.
    Borison RL; Pathiraja AP; Diamond BI; Meibach RC
    Psychopharmacol Bull; 1992; 28(2):213-8. PubMed ID: 1381102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia and severe tardive dyskinesia responsive to risperidone.
    Kopala LC; Honer WG
    J Clin Psychopharmacol; 1994 Dec; 14(6):430-1. PubMed ID: 7533794
    [No Abstract]   [Full Text] [Related]  

  • 6. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
    Potkin SG; Litman RE; Torres R; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
    Byerly MJ; Nakonezny PA; Rush AJ
    Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone in adolescents.
    Cozza SJ; Edison DL
    J Am Acad Child Adolesc Psychiatry; 1994 Oct; 33(8):1211. PubMed ID: 7527022
    [No Abstract]   [Full Text] [Related]  

  • 12. Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
    Delcker A; Schoon ML; Oczkowski B; Gaertner HJ
    Pharmacopsychiatry; 1990 May; 23(3):125-30. PubMed ID: 1973843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double blind comparison of zuclopenthixol acetate with haloperidol in the management of acutely disturbed schizophrenics.
    Chin CN; Hamid AR; Philip G; Ramlee T; Mahmud M; Zulkifli G; Loh CC; Zakariah MS; Norhamidah MS; Suraya Y; Roslan KA; Chandramohan P; Cheah YC; Leonard AO
    Med J Malaysia; 1998 Dec; 53(4):365-71. PubMed ID: 10971979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
    Czobor P; Volavka J
    J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
    Hebenstreit GF; Laux G; Schubert H; Beckmann H; Amman J; Bunse J; Eikmeier G; Geretsegger C; Kanitz RD; Kanzow WT
    Pharmacopsychiatry; 1991 Sep; 24(5):153-8. PubMed ID: 1685572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial.
    Segal J; Berk M; Brook S
    Clin Neuropharmacol; 1998; 21(3):176-80. PubMed ID: 9617509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
    Möller HJ; Pelzer E; Kissling W; Riehl T; Wernicke T
    Pharmacopsychiatry; 1991 Nov; 24(6):185-9. PubMed ID: 1725925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.